

Grifols will build new manufacturing site in Spain to double its plasma fractionation capacity in Europe

- *The new facility in Lliçà de Vall (Barcelona) is expected to begin operations in 2030 and will enable the company to produce more plasma-derived medicines to meet the needs of over 300,000 patients across the continent who rely on these treatments*
- *It will be integrated with Grifols' existing campus in Parets del Vallès, creating a 25-hectare biotechnology hub with nearly 3,700 employees and generating more than 400 specialized jobs*
- *With this investment, the company strengthens its commitment to Catalonia, Spain and Europe as it addresses the rising demand of European patients*
- *Grifols plans to power 100% of its operations with renewable electricity, while also implementing intelligent resource monitoring and management systems across a highly digitalized campus*

Barcelona, Spain, July 16, 2025 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines, today announced today that it will invest EUR 160 million in a new facility in Lliçà de Vall (Barcelona), expanding its industrial footprint in Spain and doubling its plasma fractionation capacity in Europe. With this new plant, the company will strengthen its ability to serve the more than 300,000 patients across the continent who rely on plasma-derived medicines, reinforcing its commitment to Catalonia, Spain and Europe.

Construction of the new plant will begin this year, with operations expected to start in 2030. It will join Grifols' adjacent and historic production site in Parets del Vallès to form a 25-hectare biotechnology hub. The new manufacturing complex in Lliçà de Vall, which will span over 80,000 square meters, is expected to create more than 400 highly qualified jobs once operational. With this expansion, the company's combined presence in Parets del Vallès and Lliçà de Vall will top 3,700 employees.

"Spain and Catalonia are strategic partners for our long-term growth and for jointly advancing scientific progress in healthcare, as well as the region's industrial, environmental and social development. Expanding our production capacity will allow us to meet the growing European demand for plasma-derived medicines from our new facilities. In doing so, Grifols continues to fulfill its core mission: to care for the health and well-being of the more than 300,000 European patients who rely on our therapies," said Nacho Abia, CEO of Grifols. He added: "We are especially pleased to expand our presence in the Vallès Oriental area, which we plan to call home for a long time to come."

GRIFOLS

“We are proud and delighted to welcome Grifols to Lliçà de Vall, where we look forward to collaborating together to build a sustainable and lasting relationship for the mutual benefit of the people of Lliçà and Grifols,” said the mayor of Lliçà de Vall, Xavi Castillejo.

“Parets de Vallès, home to Grifols world-class manufacturing for more than 50 years, is delighted that the company will not only continue to be an integral part of Parets but also expand right next door, establishing a powerful biotechnology center of excellence,” said Francesc Juzgado, the mayor of Parets de Vallès.

A sustainable new plant to meet growing demand

The rising regional demand for immunoglobulins and other plasma-derived medicines is driving the expansion of the complex.

The new facilities will include a plasma fractionation plant, logistics operations, a testing laboratory and warehouses. There will also be a new space for Grifols Engineering, which as a world-renowned provider of first-class biopharmaceutical installations will design and construct the Lliçà de Vall expansion.

As a recognized global leader in sustainability, Grifols will incorporate advanced technologies throughout the Lliçà de Vall site. The company expects to power 100% of operations through renewable electricity, smart resource monitoring and management systems across a highly digitalized campus to minimize unnecessary consumption and ensure energy efficiency. Circular economy best practices will make certain that materials are reused, recycled, repaired and repurposed throughout their life cycles.

Grifols: 115 years of driving economic and social value

Since its founding in 1909, Grifols has made Spain and Catalonia cornerstones of its international growth – a commitment to patients and global society that has only deepened over more than 115 years of history.

The company’s sustained investment over the decades reflects its dedication to creating new opportunities, driving socioeconomic development and generating long-term value in the region.

In addition to its approximately 4,600 direct employees in Spain, Grifols generates more than 16,000 indirect jobs, contributing over EUR 1.5 billion to the Spanish economy – figures that are expected to grow as the Lliçà de Vall complex becomes operational.

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life.

GRIFOLS

Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.